



FDA Approval Decisions Report August-October 2008

Jeremy Zhou
Senior Analyst
415-782-0454, x158
jzhou@reveredata.com

Daniel Grundig
Analyst
415-782-0454, x176
dgrundig@reveredata.com

Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** - specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

Contents

- Recent Approval Results/Updates
- Expected PDUFA Dates in the Next Three Months
- Price and Financial Info

Copyright 2008 by Revere Data, LLC. All rights reserved.

Notes:

1. Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
2. Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

For more information on Revere's independent research data and investment analytics, please contact us as follows:

Revere Data, LLC | 60 East 42nd St. Suite 716 | New York, NY 110165
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

Recent Approval Results/Updates

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Previous Expected PDUFA Date	Approval results/update
Wyeth (WYE) / Enbrel/Enbrel Once-Weekly (Etanercept)				
	Chronic Moderate-To-Severe Plaque Psoriasis In Pediatric Patients	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	Jul 2008	Complete Response Letter Received 07/24/2008
Amgen, Inc. (AMGN) / Enbrel/Enbrel Once-Weekly (Etanercept)				
	Chronic Moderate-To-Severe Plaque Psoriasis In Pediatric Patients	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	Jul 2008	Complete Response Letter Received 07/24/2008
Noven Pharmaceuticals, Inc. (NOVN) / Stavzor (Delayed Release Valproic Acid Capsules)				
	Migraine Headache Prophylaxis	Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors	Jul 2008	Approved 07/30/2008
Noven Pharmaceuticals, Inc. (NOVN) / Stavzor (Delayed Release Valproic Acid Capsules)				
	Manic Episodes Associated With Bipolar Disorder	Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors	Jul 2008	Approved 07/30/2008
Noven Pharmaceuticals, Inc. (NOVN) / Stavzor (Delayed Release Valproic Acid Capsules)				
	Monotherapy And Adjunctive Therapy In Multiple Seizure Types Including Epilepsy	Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors	Jul 2008	Approved 07/30/2008
Johnson & Johnson (JNJ) / Doribax (Doripenem)				
	Nosocomial Pneumonia	Carbapenems	07/04/2008	Rescheduled to 08/04/2008
Sciele Pharma Inc. (SCRX) / LARx (Head Lice Asphyxiate)				
	Head Lice Treatment	Asphyxiates	<u>07/15/2008</u>	Approvable Letter Received 07/16/2008
Warner Chilcott Ltd. (WCRX) / Topical Alprostadil Cream/Formerly Alprox-TD				
	Erectile Dysfunction (ED)	Vasodilatory Agents	<u>07/18/2008</u>	Non-Approvable Letter Received 07/22/2008
NexMed, Inc. (NEXM) / Topical Alprostadil Cream/Formerly Alprox-TD				
	Erectile Dysfunction (ED)	Vasodilatory Agents	<u>07/18/2008</u>	Non-Approvable Letter Received 07/22/2008
Theravance, Inc. (THRX) / Telavancin				
	Complicated Skin And Soft Tissue Infections Caused By Gram-Positive Bacteria (cSSTIs)	Glycopeptides	<u>07/21/2008</u>	Approvable Letter Received 10/22/2007
Sanofi-Aventis SA (ADR) (SNY) / Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)				
	Human Papillomavirus (HPV) Vaccine, Cervical Cancer Vaccine, Prevention Of Genital Warts In Women 27 To 45 Years Of Age	Papillomavirus, Papillomavirus Vaccines	07/21/2008	Approvable Letter Received 06/25/2008
Merck & Co., Inc. (MRK) / Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)				
	Human Papillomavirus (HPV) Vaccine, Cervical Cancer Vaccine, Prevention Of Genital Warts In Women 27 To 45 Years Of Age	Papillomavirus, Papillomavirus Vaccines	07/21/2008	Approvable Letter Received 06/25/2008
Amgen, Inc. (AMGN) / Nplate (Romiplostim)				
	Chronic Immune Thrombocytopenia Pupura (ITP)	Platelet Growth Factors	<u>07/23/2008</u>	Result Pending

Company (Symbol) / Drug Candidate			
Schering-Plough Corporation (SGP) / Organon Asenapine			
Schizophrenia	Serotonin/Dopamine Receptor Blocking Agents	<u>07/25/2008</u>	Result Pending
Schering-Plough Corporation (SGP) / Organon Asenapine			
Bipolar Disorder	Serotonin/Dopamine Receptor Blocking Agents	<u>07/25/2008</u>	Result Pending
Vanda Pharmaceuticals Inc. (VNDA) / Fanapta (Oral Iloperidone)			
Schizophrenia	Serotonin/Dopamine Receptor Blocking Agents	<u>07/25/2008</u>	Non-Approvable Letter Received 07/25/2008
Titan Pharmaceuticals, Inc. (TTP) / Fanapta (Iloperidone)			
Schizophrenia	Serotonin/Dopamine Receptor Blocking Agents	<u>07/25/2008</u>	Non-Approvable Letter Received 07/25/2008
Eisai Co., Ltd (ADR) (ESALY) / MGi Pharma AQUAVAN Injection (Fospropofol Disodium Injection)			
Anesthesia/Sedation In Patients Undergoing Conscious Sedation During Colonoscopy/Bronchoscopy	Hypnotic Agents (Sedatives)	<u>07/25/2008</u>	Non-Approvable Letter Received 07/25/2008
CV Therapeutics, Inc. (CVTX) / Ranexa (Ranolazine)			
Arrhythmia	Adenosine A1 Receptor Agonists, Partial Fatty Acid Oxidation Inhibitors (pFOX Inhibitors)	<u>07/25/2008</u>	Result Pending
CV Therapeutics, Inc. (CVTX) / Ranexa (Ranolazine)			
Reduction Of Hemoglobin A1c (HbA1c) In Coronary Artery Disease Patients With Diabetes	Adenosine A1 Receptor Agonists, Partial Fatty Acid Oxidation Inhibitors (pFOX Inhibitors)	<u>07/25/2008</u>	Result Pending
CV Therapeutics, Inc. (CVTX) / Ranexa (Ranolazine)			
First-Line Treatment Of Chronic Stable Angina	Adenosine A1 Receptor Agonists, Partial Fatty Acid Oxidation Inhibitors (pFOX Inhibitors)	<u>07/25/2008</u>	Result Pending

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases.

Expected PDUFA Dates in the Next Three Months

August Drug Candidates

Companies

BioDelivery Sciences International, Inc. (BDSI)
Eisai Co., Ltd (ADR) (ESALY)
Gilead Sciences, Inc. (GILD)
Johnson & Johnson (JNJ)

Sectors

- Biopharmaceuticals
- ◆ Digestive System
- ◆ Infectious Diseases
- ◆ Pain Management

Notes:

1. Some drug candidates are filed jointly by two companies.
2. Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Johnson & Johnson (JNJ) / Doribax (Doripenem)						
	Nosocomial Pneumonia	Carbapenems	08/04/2008	Yes	Yes Invanz (Ertapenem Sodium) / (MRK)	No
Gilead Sciences, Inc. (GILD) / Viread (Tenofovir Disoproxil Fumarate)						
	Chronic Hepatitis B Virus (HBV)	Nucleoside Reverse Transcriptase Inhibitors (NRTI), Reverse Transcriptase Inhibitors (Nucleoside Analogs)	<u>08/11/2008</u>	Yes	No Multiple Drugs	No
Eisai Co., Ltd (ADR) (ESALY) / MGi Pharma Oral Aloxi (Palonosetron)						
	Chemotherapy Induced Nausea And Vomiting	Serotonin Receptor Antagonists	<u>08/22/2008</u>	Yes	No Multiple Drugs	No
BioDelivery Sciences International, Inc. (BDSI) / BEMA Fentanyl						
	Breakthrough Cancer Pain In Opioid Tolerant Patients	Opioids	08/29/2008	Yes	No Multiple Drugs	Yes

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? 1st/2nd Drug -- 1st or 2nd FDA Approved Drug of the Company?

September Drug Candidates

Companies

Abbott Laboratories (ABT)
 Cephalon, Inc. (CEPH)
 Eli Lilly & Co. (LLY)
 Genentech, Inc. (DNA)
 General Electric Company (GE)
 Gilead Sciences, Inc. (GILD)
 GlaxoSmithKline plc (ADR) (GSK)
 Ligand Pharmaceuticals Inc. (LGND)
 Novadel Pharma Inc (NVD)
 OSI Pharmaceuticals, Inc. (OSIP)
Roche Holding Ltd. (ADR) (RHHBY) [2]

Sectors

- Biopharmaceuticals
 - ◆ Cardiovascular System
 - ◆ Hematology
 - ◆ Immunology
 - ◆ Musculoskeletal System
 - ◆ Neurology
 - ◆ Oncology
 - ◆ Pain Management
 - ◆ Respiratory System
- Medical Devices
 - ◆ Radiology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Abbott Laboratories (ABT) / Vicodin CR (Controlled Release Acetaminophen/Hydrocodone)						
	Moderate To Moderately Severe Pain	Analgesics/Opioids	Sep 2008	Yes	No Multiple Drugs	No
Roche Holding Ltd. (ADR) (RHHBY) / Tarceva (Erlotinib)						
	New Maximum Tolerated Dose (MTD) For Smokers With Non-Small Cell Lung Cancer (NSCLC)	Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors	Sep 2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
OSI Pharmaceuticals, Inc. (OSIP) / Tarceva (Erlotinib)						
	New Maximum Tolerated Dose (MTD) For Smokers With Non-Small Cell Lung Cancer (NSCLC)	Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors	Sep 2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Genentech, Inc. (DNA) / Tarceva (Erlotinib)						
	New Maximum Tolerated Dose (MTD) For Smokers With Non-Small Cell Lung Cancer (NSCLC)	Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors	Sep 2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Cephalon, Inc. (CEPH) / Fentora (Fentanyl Buccal Tablet)						
	Management Of Breakthrough Pain In Opioid Tolerant Patients With Chronic Pain Conditions	Opioids	<u>09/12/2008</u>	Yes	Yes ALZA Duragesic (Fentanyl) / (JNJ) Embeda (Abuse Resistant Morphine Sulphate/Naltrexone) / (ALO)	No
Gilead Sciences, Inc. (GILD) / Inhaled Aztreonam Lysine						
	Pulmonary Infection Related To Cystic Fibrosis (CF)	Monobactams	<u>09/16/2008</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Roche Holding Ltd. (ADR) (RHHBY) / Actemra (Tocilizumab)						
	Rheumatoid Arthritis (RA)	Monoclonal Antibodies	09/19/2008	Yes	Yes Ocrelizumab/R1594 (Humanized Anti-CD20 Monoclonal Antibody) / (DNA) Golimumab / (SGP)	No
Ligand Pharmaceuticals Inc. (LGND) / Promacta (Eltrombopag)						
	Idiopathic Thrombocytopenia Purpura (ITP)/Thrombocytopenia	Thrombopoietin Agonists	<u>09/19/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
GlaxoSmithKline plc (ADR) (GSK) / Promacta (Eltrombopag)						
	Idiopathic Thrombocytopenia Purpura (ITP)/Thrombocytopenia	Thrombopoietin Agonists	<u>09/19/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
General Electric Company (GE) / GE Healthcare AdreView (Iobenguane I 123 Injection)						
	Detection Of Neuroendocrine Cancer In Pediatric And Adult Patients	Injectable	<u>09/19/2008</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Novadel Pharma Inc (NVD) / ZolpiMist (Zolpidem Tartrate Oral Spray)						
	Short-Term Treatment Of Insomnia	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	09/23/2008	Yes	No Multiple Drugs	Yes
Eli Lilly & Co. (LLY) / Prasugrel						
	Acute Coronary Syndrome (ACS) In Patients Undergoing Percutaneous Coronary Intervention	Adenosine Diphosphate (ADP) Inhibitors	<u>09/26/2008</u>	Yes	Yes Plavix (Clopidogrel Bisulfate) / (BMY) AZD6140 (ADP Antagonist) / (AZN)	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

October Drug Candidates

Companies

Abbott Laboratories (ABT)
 AMAG Pharmaceuticals, Inc. (AMAG)
 Barr Pharmaceuticals, Inc. (BRL)
 Cephalon, Inc. (CEPH)
 Cipher Pharmaceuticals Inc (DND:CA)
 Cypress Bioscience, Inc. (CYPB)
 Enzon Pharmaceuticals, Inc. (ENZN)
 Forest Laboratories, Inc. (FRX)
Johnson & Johnson (JNJ) [2]
 Medarex inc. (MEDX)
 Nektar Therapeutics (NKTR)
 Salix Pharmaceuticals, Ltd. (SLXP)
 Watson Pharmaceuticals, Inc. (WPI)

Sectors

- Biopharmaceuticals
- ◆ Dermatology
- ◆ Digestive System
- ◆ Endocrinology/Metabolism
- ◆ Hematology
- ◆ Immunology
- ◆ Infectious Diseases
- ◆ Musculoskeletal System
- ◆ Obstetrics/Gynecology
- ◆ Oncology
- ◆ Pain Management
- ◆ Urology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Abbott Laboratories (ABT) / TriLipix (Next Generation Fenofibrate)						
	Hypertriglyceridemia, Hypercholesterolemia	Plasma Triglyceride Reducing Agents (Fibrate Compounds)	Oct 2008	Yes	Yes ANTARA (Fenofibrate) / (OSCI) Lipofen (Fenofibrate Lidose Delivery) / (DND:CA)	No
Medarex inc. (MEDX) / CNTO 1275 (Ustekinumab)						
	Chronic Moderate To Severe Plaque Psoriasis	Monoclonal Antibodies	10/03/2008	Yes	Yes Raptiva (Efalizumab) / (DNA)	Yes
Johnson & Johnson (JNJ) / Centocor CNTO 1275 (Ustekinumab)						
	Chronic Moderate To Severe Plaque Psoriasis	Monoclonal Antibodies	10/03/2008	Yes	Yes Raptiva (Efalizumab) / (DNA)	No
Nektar Therapeutics (NKTR) / Cimzia (Certolizumab Pegol)						
	Rheumatoid Arthritis (RA)	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	10/06/2008	Yes	No Multiple Drugs	No
Enzon Pharmaceuticals, Inc. (ENZN) / Cimzia (Certolizumab Pegol)						
	Rheumatoid Arthritis (RA)	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	10/06/2008	Yes	No Multiple Drugs	No
Watson Pharmaceuticals, Inc. (WPI) / Silodosin						
	Benign Prostate Hyperplasia (BPH)	Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)	10/10/2008	Yes	No Multiple Drugs	No
Cipher Pharmaceuticals Inc (DND:CA) / CIP-Tramadol Hydrochloride Extended Release						
	Moderate To Moderately Severe Pain	Opioids	10/13/2008	Yes	No Multiple Drugs	Yes
AMAG Pharmaceuticals, Inc. (AMAG) / Ferumoxytol						
	Iron Deficiency Anemia In Patients With Chronic Kidney Disease (CKD)	Iron Supplements, Oral	10/17/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Johnson & Johnson (JNJ) / Prezista (Darunavir)						
	Human Immunodeficiency Virus (HIV)-1-Infected, Treatment-naive Adults	Protease Inhibitors	10/21/2008	Yes	No Multiple Drugs	No

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Barr Pharmaceuticals, Inc. (BRL) / Lo Seasonique (Levonorgestrel/Ethinyl Estradiol)						
	Pregnancy Prevention/Contraception	Estrogens/Progestins	<u>10/24/2008</u>	Yes	No Multiple Drugs	No
Cypress Bioscience, Inc. (CYPB) / Milnacipran						
	Fibromyalgia Syndrome (FMS)	Serotonin/Norepinephrine Reuptake Inhibitors	10/31/2008	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
Forest Laboratories, Inc. (FRX) / Milnacipran						
	Fibromyalgia Syndrome (FMS)	Serotonin/Norepinephrine Reuptake Inhibitors	10/31/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Cephalon, Inc. (CEPH) / Treanda (Bendamustine Hydrochloride)						
	Indolent Non-Hodgkin's Lymphoma (NHL) Refractory To Rituxumab	Nitrogen Mustard Type	10/31/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Salix Pharmaceuticals, Ltd. (SLXP) / Granulated Mesalamine						
	Ulcerative Colitis Remission Maintenance	Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors	<u>10/31/2008</u>	Yes	Yes Asacol (Mesalamine) / (PG) Pentasa (Mesalamine) / (SHPGY)	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

Price and Financial Info

August 2008

Data as of 08/01/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
BioDelivery Sciences International, Inc.	BDSI	2.54	48.642	30,298	n/a	0	10.0	-29.64%	-29.77%
Eisai Co., Ltd (ADR)	ESALY	35.61	10,145.217	1,992	27.89	88.18	1,119.5	-16.21%	-16.34%
Gilead Sciences, Inc.	GILD	53.90	49,717.043	11,337,904	13.18	0	2,908.4	45.27%	45.14%
Johnson & Johnson	JNJ	68.29	192,454.328	13,976,244	n/a	n/a	n/a	12.02%	11.89%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

September 2008

Data as of 08/01/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Abbott Laboratories	ABT	56.23	86,681.190	8,683,948	40.17	73.24	5,178.3	10.36%	10.23%
Cephalon, Inc.	CEPH	74.38	5,038.755	1,470,226	27.71	70.32	673.4	4.76%	4.63%
Eli Lilly & Co.	LLY	47.19	53,653.852	5,961,444	4.33	31.31	5,170.0	-12.93%	-13.06%
Genentech, Inc.	DNA	95.12	99,960.848	7,499,496	n/a	n/a	n/a	27.85%	27.72%
General Electric Company	GE	28.37	282,207.650	67,374,816	15.67	469.74	18,989.0	-27.17%	-27.30%
Gilead Sciences, Inc.	GILD	53.90	49,717.043	11,337,904	13.18	0	2,908.4	45.27%	45.14%
GlaxoSmithKline plc (ADR)	GSK	46.44	121,682.878	2,538,860	52.81	184.5	11,321.5	-10.02%	-10.15%
Ligand Pharmaceuticals Inc.	LGND	3.68	349.299	331,624	9.47	4.45	90.2	-34.98%	-35.11%
Novadel Pharma Inc	NVD	0.28	16.994	54,684	7.03	10.67	2.3	-58.82%	-58.95%
OSI Pharmaceuticals, Inc.	OSIP	52.20	2,985.671	1,511,137	n/a	n/a	n/a	63.84%	63.71%
Roche Holding Ltd. (ADR)	RHHBY	92.29	159,211.782	421,072	6.25	13.43	15,123.5	3.58%	3.45%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

October 2008

Data as of 08/01/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Abbott Laboratories	ABT	56.23	86,681.190	8,683,948	40.17	73.24	5,178.3	10.36%	10.23%
AMAG Pharmaceuticals, Inc.	AMAG	41.25	700.990	445,771	n/a	n/a	n/a	-22.26%	-22.39%
Barr Pharmaceuticals, Inc.	BRL	66.45	7,180.813	5,532,237	31.09	99.46	505.0	28.36%	28.23%
Cephalon, Inc.	CEPH	74.38	5,038.755	1,470,226	27.71	70.32	673.4	4.76%	4.63%
Cipher Pharmaceuticals Inc	DND:CA	0.82	19.725	3,638	1.33	0	10.3	-59.00%	-59.13%
Cypress Bioscience, Inc.	CYPB	8.74	328.068	266,453	2.32	0	154.1	-25.93%	-26.06%
Enzon Pharmaceuticals, Inc.	ENZN	8.26	369.539	440,364	n/a	716.78	129.1	15.22%	15.09%
Forest Laboratories, Inc.	FRX	34.91	10,639.109	2,325,776	n/a	n/a	n/a	-14.52%	-14.65%
Johnson & Johnson	JNJ	68.29	192,454.328	13,976,244	n/a	n/a	n/a	12.02%	11.89%
Medarex inc.	MEDX	9.93	1,267.299	2,017,054	3.20	36.33	464.5	-30.95%	-31.08%
Nektar Therapeutics	NKTR	4.76	439.833	1,179,916	4.64	192.64	412.6	-38.58%	-38.71%
Salix Pharmaceuticals, Ltd.	SLXP	7.78	371.518	383,222	4.62	6.19	111.5	-30.22%	-30.34%
Watson Pharmaceuticals, Inc.	WPI	29.62	3,093.542	972,520	6.98	43.47	186.7	-2.41%	-2.53%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,